

Docket No. 4874-7000

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): Zhilov et al.

Group Art Unit: Unassigned

National Stage of: International Application
No. PCT/RU2003/000346

Examiner: Unassigned

Int'l Filing Date: August 4, 2003

Submitted: Herewith

For: **CYCLIC BIOISOSTERES OF DERIVATIVES OF A PURINE SYSTEM
AND PHARMACEUTICAL COMPOSITION BASED THEREON**

INFORMATION DISCLOSURE STATEMENT

Mail Stop PCT
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

This Information Disclosure Statement is filed in accordance with 37 C.F.R.

§§1.56, 1.97 and 1.98. The items listed on Form PTO-1449, a copy of which is enclosed, are made of record to assist the Patent and Trademark Office in its examination of this application.

The Examiner is respectfully requested to fully consider the items and to independently ascertain their teaching.

1. ☐ For each of the following items listed on the enclosed copy of Form PTO-1449 that is not in the English language, an English language translation of that item or a portion thereof or a concise explanation of the relevance of that item is enclosed:

2. ☒ For each of the following items listed on the enclosed copy of Form PTO-1449 that is not in the English language, a concise explanation of the relevance of that item is indicated in the enclosed International Search Report or described in the specification.

Serial No.: National Phase of PCT/RU2003/000346

3. ☐ Any copy of the items listed on the enclosed copy of Form PTO-1449 that is not enclosed with this Information Disclosure Statement was previously cited by or submitted to the Patent and Trademark Office in application Serial No. _____, filed _____.
4. ☒ No fee is due under 37 C.F.R. §1.17(p) for this Information Disclosure Statement since it is being filed in compliance with:
- ☐ 37 C.F.R. §1.97(b)(1), within three months of the filing date of a national application other than a CPA; or
 - ☒ 37 C.F.R. §1.97(b)(2), within three months of the date of entry into the national stage as set forth in §1.491 in an international application; or
 - ☐ 37 C.F.R. §1.97(b)(3), before the mailing date of a first Office action on the merits; or
 - ☐ 37 C.F.R. §1.97(b)(4), before the mailing date of a first office action after the filing of an RCE under §1.114.
- ☒ The Commissioner is hereby authorized to charge any additional fees which may be required for this Information Disclosure Statement, or credit any overpayment to Deposit Account No. 13-4500, Order No. 4874-7000. A DUPLICATE COPY OF THIS SHEET IS ATTACHED.

Respectfully submitted,
MORGAN & FINNEGAN, L.L.P.

Dated: February 3, 2006

By: 

Michael S. Marcus
Registration No. 31,727
(202) 857-7887 Telephone
(202) 857-7929 Facsimile

Correspondence Address:

MORGAN & FINNEGAN, L.L.P.
3 World Financial Center
New York, NY 10281-2101

FORM PTO-1449A INFORMATION DISCLOSURE CITATION	Attorney Docket: 4874-7000	National Stage of International Application No. PCT/RU2003/000346
Applicant: Zhilov et al.		
Filing Date: August 4, 2003		Group Art Unit: Unknown

U.S. PATENT / PUBLICATION DOCUMENTS

Examiner Initial	Patent/Publication Number	Publication/Issue Date	Name	Filing Date
	1.	5719151	02-1998	Shall et al.
	2.	5753706	05-1998	Hsu
	3.	5196432	03-1993	Crichlow
	4.	5597820	01-1997	Hori et al.
	5.	5723496	03-1998	Nakada
	6.	5256660	10-1993	Swan
	7.			
	8.			
	9.			
	10.			
	11.			
	12.			
	13.			
	14.			

FOREIGN PATENT DOCUMENTS

Examiner Initial	Patent Number	Publication Date	Country	Copy Filed	Translation
	15.	2 211 036	08-2003	Russia	<input checked="" type="checkbox"/> Yes (Abstract Only)
	16.	2 163 122	02-2001	Russia	<input checked="" type="checkbox"/> Yes (Abstract Only)
	17.	2 169 139	06-2001	Russia	<input checked="" type="checkbox"/> Yes (Abstract Only)
	18.	2 168 511	08-1998	Russia	<input checked="" type="checkbox"/> Yes (Abstract Only)
	19.	05-078356	03-1993	Japan	<input checked="" type="checkbox"/> Yes (Abstract Only)
	20.	2 185 173	07-2002	Russia	<input checked="" type="checkbox"/> Yes (Abstract Only)

Examiner	Date Considered
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP §609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.	